Vol.

No.

November 22, 2024Nov 22, 2024

DOWNLOAD THE PDF

As Trump’s second term nears, Republican support for NIH is at a low point By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research

Cover Story

Capitol Hill

As Trump’s second term nears, Republican support for NIH is at a low point

By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research

By Paul Goldberg

The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.

Patient navigation benefits health systems, improves care
Initial data presented at the White House come a year after CMS payment began

By Jacquelyn Cobb

Health Equity

Cedars-Sinai spearheads first national certification program for COE staff at cancer centers

By McKenzie Prillaman

Clinical Trials & Tribulations

Menin inhibitors emerge as new treatment for advanced AML

By Ghayas Issa

Free In the Archives

Larry Einhorn reflects on his pioneering work on platinum-based chemotherapy at the AACI/CCAF annual meeting

By McKenzie Prillaman

In Brief

Krish Patel joins Sarah Cannon as director of lymphoma research

Robert Schnoll named John H. Glick, MD Professor in Cancer Research at Penn Medicine

William Oh named service medical director at Smilow Cancer Hospital at Greenwich

Roy Herbst receives Ezra Greenspan Award from Chemotherapy+ Foundation

Two Neds—Ned David and Ned Sharpless—form Jupiter Bioventures and close $70M in initial financing

Argonne National Laboratory receives $22M from ARPA-H to accelerate cancer therapy, vaccine discoveries using AI

University of Cincinnati receives $2.3M from NCI to visualize CAR T cells within the body

Northwell invests $1.2M to develop program to treat tumors with noninvasive targeted ultrasound beams

CPRIT awards $89M in grants

The Lilabean Foundation for Pediatric Brain Cancer raises $900K

TD Bank recommits $100K to MUSC Hollings’s SC AMEN program

Clinical Roundup

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

American Lung Association’s “State of Lung Cancer” report points to stark differences in survival, screening and treatment across states

Phase III trial of subcutaneous pembrolizumab with berahyaluronidase alfa meets primary endpoints

Exact Sciences data show multi-biomarker class approach improves MCED cancer detection

Mushroom supplement may slow prostate cancer progression, City of Hope study finds

Nivolumab + epigenetic drug induce immune response in some resistant pancreatic cancers

Remote telemedicine tool found highly accurate in diagnosing melanoma

UVA Health tests focused ultrasound to increase immune response in melanoma

Model created by Cedars-Sinai investigators could speed patient selection for clinical trials

VHIO’s novel CAR T-cell therapy demonstrates efficacy and safety in preclinical models of HER2-positive solid tumors

Hemokine modulatory regimen shows promise for TNBC in phase I study

Fralin Biomedical Research Institute spinoff company focuses on peptide drugs targeting cancer stem cells

Drugs & Targets

FDA approves new alternative standard related to mammography report assessments

FDA approves revumenib for r/r acute leukemia with a KMT2A translocation

FDA approves Ziihera for HER2+ biliary tract cancer

FDA accepts sNDA for prostate cancer treatment

FDA approves first companion diagnostic for lung cancer drug

CHMP issues positive opinion of Sarclisa for transplant-ineligible newly diagnosed MM

EC approves of Elahere for treatment of platinum-resistant ovarian cancer

LINDIS Biotech signs licensing agreement with Pharmanovia for the commercialization of catumaxomab

Sheba Medical Center, Roche collaborate to transform NSCLC diagnostics with AI-powered digital pathology

Immunai to collaborate with Teva to enhance clinical decision making in immuno-oncology clinical trials

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

As Trump’s second term nears, Republican support for NIH is at a low point

In Brief

Clinical Roundup

Drugs & Targets

Recent Issues

Never miss an issue!

Login